All Patients Dosed in Phase II Clinical Trial of RECCE 327 Topical Gel for Skin Infections.

Recce Pharmaceuticals Limited (ASX: RCE) has completed dosing all 30 patients in its Phase II clinical trial of RECCE 327 Topical Gel (R327G) for Acute Bacterial Skin and Skin Structure Infections (ABSSSI). Preliminary results indicate patients showed either complete cures or significant improvement in symptoms, with no serious adverse events reported. Full Phase II data is expected in Q1 2025, and preparations for Phase III trials are underway, marking significant progress toward regulatory approval. 

Additionally, plans for a registrational Phase III trial in Indonesia for diabetic foot infections are advancing, unlocking regional commercial opportunities. With the global ABSSSI market projected to grow substantially in the coming years, R327G addresses a crucial need for effective treatments against resistant bacterial infections. This development highlights its potential impact on improving patient outcomes and combating antimicrobial resistance globally.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com